# Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)

> **NCT03208296** · PHASE1,PHASE2 · SUSPENDED · sponsor: **Ascend Biopharmaceuticals Ltd** · enrollment: 24 (estimated)

## Conditions studied

- Basal Cell Carcinoma in Basal Cell Nevus Syndrome

## Interventions

- **BIOLOGICAL:** ASN-002

## Key facts

- **NCT ID:** NCT03208296
- **Lead sponsor:** Ascend Biopharmaceuticals Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2017-12-01
- **Primary completion:** 2024-12-31
- **Final completion:** 2025-03-31
- **Target enrollment:** 24 (ESTIMATED)
- **Why stopped:** Study did not start. Another protocol is being developed. Recruitment on hold.
- **Last updated:** 2023-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03208296

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03208296, "Study of ASN-002 to Treat Basal Cell Carcinomas (BCCs) in Individuals With Basal Cell Nevus Syndrome (BCNS)". Retrieved via AI Analytics 2026-05-21 from https://api.ai-analytics.org/clinical/NCT03208296. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*